A Randomized, Double-blind, Placebo-controlled, Phase 2, 6-month Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies

Grants and Contracts Details

StatusActive
Effective start/end date10/17/228/23/24

Funding

  • Cognition Therapeutics Incorporated: $98,103.00